300k
newly diagnosed breast cancer patients every year in the U.S.1
SOZO® Digital Health Platform is the only FDA-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. A systemwide, cloud-based solution that is setting new standards in early detection and management of breast cancer-related lymphedema for patients across the care continuum.
Discover SOZOIn PREVENT, the largest randomized controlled trial (RCT) for lymphedema prevention in breast cancer patients, 92% of patients with early detection using BIS and intervention did not progress to chronic lymphedema.
Using our SOZO Digital Health Platform with L-Dex, ImpediMed partners with you to implement a Lymphedema Prevention Program (LPP) to help detect lymphedema in breast cancer patients at the early stage, so that it can be treated and stopped from progressing to a lifelong condition.